HCPLive Network

Plaque Psoriasis

The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Individuals with hypertension and those with long-term, regular use of beta-blocker medication may be at increased risk of developing psoriasis flares, according to research published online July 2 in JAMA Dermatology.
As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.
For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.
Patients with psoriasis, psoriatic arthritis, or both conditions felt their quality of life decreased if they experienced condition symptoms in more parts of their body.
Plaque Psoriasis Upcoming Events
Paris, France
June 11-14, 2014
New York, NY
July 9-12, 2014
Chicago, IL
August 6-10, 2014
Louisville, KY
August 7-9, 2014
Las Vegas, NV
September 12-13, 2014
Sonoma, CA
September 24-27, 2014
Las Vegas, NV
October 16-19, 2014
Dallas, TX
October 24-26, 2014
Boston, MA
November 14-19, 2014
New Orleans, LA
April 27-29, 2015
$AD300x250BB$